Clinical trial · Observational
HyperArc Registry Study
NCT05270707CI-TRIAL-00095738completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| CNS Disorder, Intracranial | — | UNRESOLVED | — |
| CNS Neoplasm | Central Nervous System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic radiosurgery | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Survival
- timeFrame
- follow until death, on average approximately 2 years
- description
- Survival
Secondary outcomes (2)
- measure
- Local tumor control
- timeFrame
- follow until death, on average approximately 2 years
- description
- Response of treated tumors
- measure
- HyperArc Patterns of Care
- timeFrame
- Limited to course of treatment: up to 4 weeks
- description
- Dosimetry information for clinically delivered HyperArc treatments
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Received or scheduled to receive treatment using the HyperArc treatment method * Age of legal adult according to local law * Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board Exclusion Criteria: * None, apart from not meeting Inclusion Criteria
References
Publications (0)
Data not yet available
No reference posted for this study.